US 12,265,081 B2
Filovirus antibodies and methods
Ravi Durvasula, Albuquerque, NM (US); Steven Bradfute, Albuquerque, NM (US); and Adinarayana Kunamneni, Albuquerque, NM (US)
Assigned to UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US)
Appl. No. 17/436,782
Filed by UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US); Ravi Durvasula, Albuquerque, NM (US); Steven Bradfute, Albuquerque, NM (US); and Adinarayana Kunamneni, Albuquerque, NM (US)
PCT Filed Mar. 4, 2020, PCT No. PCT/US2020/020982
§ 371(c)(1), (2) Date Sep. 7, 2021,
PCT Pub. No. WO2020/185464, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/815,435, filed on Mar. 8, 2019.
Claims priority of provisional application 62/890,788, filed on Aug. 23, 2019.
Prior Publication US 2023/0212268 A1, Jul. 6, 2023
Int. Cl. G01N 33/569 (2006.01); A61P 31/14 (2006.01); C07K 16/10 (2006.01)
CPC G01N 33/56983 (2013.01) [A61P 31/14 (2018.01); C07K 16/10 (2013.01); C07K 16/1018 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. An antibody comprising:
Complementarity Determining Region (CDR) 1 variable heavy chain (VH) of EbovGPscFv4-2 (SEQ ID NO:30);
CDR2 VH of EbovGPscFv4-2 (SEQ ID NO:30);
CDR3 VH of EbovGPscFv4-2 (SEQ ID NO:30);
CDR1 variable light chain (VL) of EbovGPscFv4-2 (SEQ ID NO:30);
CDR2 VL of EbovGPscFv4-2 (SEQ ID NO:30); or
CDR3 VL of EbovGPscFv4-2 (SEQ ID NO:30).